Primecap Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$60.5M Sell
266,870
-20
-0% -$3.56K 0.04% 191
2026
Q1
$46M Hold
266,890
0.04% 195
2025
Q4
$53.2M Sell
266,890
-3,650
-1% -$662K 0.04% 190
2025
Q3
$42.3M Sell
270,540
-60
-0% -$9.53K 0.03% 203
2025
Q2
$41.1M Sell
270,600
-2,290
-0.8% -$305K 0.03% 204
2025
Q1
$41.1M Sell
272,890
-90
-0% -$15.1K 0.03% 198
2024
Q4
$50.4M Sell
272,980
-640
-0.2% -$123K 0.04% 188
2024
Q3
$53.9M Sell
273,620
-110
-0% -$22.9K 0.04% 181
2024
Q2
$56.5M Sell
273,730
-200
-0.1% -$45.3K 0.04% 179
2024
Q1
$74.2M Hold
273,930
0.06% 160
2023
Q4
$64.8M Hold
273,930
0.05% 167
2023
Q3
$53.7M Sell
273,930
-50
-0% -$10.3K 0.05% 176
2023
Q2
$57.6M Hold
273,980
0.05% 169
2023
Q1
$55.3M Sell
273,980
-10,760
-4% -$2.44M 0.05% 171
2022
Q4
$62M Sell
284,740
-10,080
-3% -$2.2M 0.06% 162
2022
Q3
$58M Sell
294,820
-1,040
-0.4% -$225K 0.06% 165
2022
Q2
$63.3M Sell
295,860
-29,030
-9% -$7.09M 0.06% 160
2022
Q1
$92.3M Sell
324,890
-32,890
-9% -$10.1M 0.07% 157
2021
Q4
$135M Sell
357,780
-7,040
-2% -$2.74M 0.09% 140
2021
Q3
$151M Sell
364,820
-690
-0.2% -$287K 0.11% 130
2021
Q2
$135M Sell
365,510
-4,750
-1% -$1.59M 0.09% 141
2021
Q1
$107M Sell
370,260
-170
-0% -$47.3K 0.07% 150
2020
Q4
$92.6M Sell
370,430
-1,070
-0.3% -$255K 0.07% 153
2020
Q3
$84.1M Sell
371,500
-5,100
-1% -$1.06M 0.07% 148
2020
Q2
$65.7M Sell
376,600
-1,500
-0.4% -$239K 0.06% 159
2020
Q1
$47.7M Sell
378,100
-4,100
-1% -$615K 0.05% 160
2019
Q4
$58.4M Sell
382,200
-1,400
-0.4% -$194K 0.04% 166
2019
Q3
$50.8M Sell
383,600
-11,400
-3% -$1.53M 0.04% 168
2019
Q2
$56M Sell
395,000
-9,000
-2% -$1.22M 0.04% 171
2019
Q1
$58.7M Sell
404,000
-100
-0% -$13.1K 0.04% 173
2018
Q4
$45.7M Sell
404,100
-17,000
-4% -$2.13M 0.04% 178
2018
Q3
$56.7M Sell
421,100
-3,000
-0.7% -$370K 0.04% 176
2018
Q2
$47.6M Sell
424,100
-200
-0% -$21.6K 0.04% 182
2018
Q1
$45.3M Sell
424,300
-1,600
-0.4% -$172K 0.03% 181
2017
Q4
$46.6M Sell
425,900
-300
-0.1% -$32.6K 0.04% 179
2017
Q3
$46M Sell
426,200
-26,800
-6% -$2.75M 0.04% 177
2017
Q2
$45.8M Sell
453,000
-421,000
-48% -$38.8M 0.04% 183
2017
Q1
$78.6M Sell
874,000
-1,000
-0.1% -$84.9K 0.07% 147
2016
Q4
$66.7M Sell
875,000
-34,660
-4% -$2.63M 0.07% 142
2016
Q3
$75.8M Sell
909,660
-61,000
-6% -$5.11M 0.08% 139
2016
Q2
$80M Sell
970,660
-242,500
-20% -$20M 0.09% 134
2016
Q1
$92.1M Sell
1,213,160
-58,222
-5% -$4.31M 0.1% 135
2015
Q4
$102M Sell
1,271,382
-165,978
-12% -$12M 0.1% 126
2015
Q3
$91.3M Sell
1,437,360
-184,940
-11% -$13.3M 0.1% 135
2015
Q2
$114M Hold
1,622,300
0.11% 132
2015
Q1
$129M Sell
1,622,300
-70,300
-4% -$5.19M 0.13% 123
2014
Q4
$108M Sell
1,692,600
-200
-0% -$12.5K 0.11% 127
2014
Q3
$101M Sell
1,692,800
-4,000
-0.2% -$229K 0.11% 122
2014
Q2
$90.8M Sell
1,696,800
-1,000
-0.1% -$54.9K 0.1% 134
2014
Q1
$102M Hold
1,697,800
0.12% 124
2013
Q4
$90.1M Hold
1,697,800
0.11% 124
2013
Q3
$78.5M Buy
1,697,800
+57,900
+4% +$2.66M 0.1% 126
2013
Q2
$67.3M Buy
+1,639,900
New +$70.3M 0.1% 126

Other funds holding CRL

Primecap Management's CRL Position: Q2 2026 in Review

Primecap Management reduced its Charles River Laboratories (CRL) stake by 0.01% in Q2 2026, selling an estimated $3.56K and leaving 266,870 shares worth $60.5M. The position accounts for 0.04% of the portfolio, ranked #191.

Primecap Management first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $151M in Q3 2021. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Primecap Management held 266,870 shares of Charles River Laboratories worth $60.5M as of Q2 2026.
  • Primecap Management sold 20 Charles River Laboratories shares in Q2 2026, an estimated $3.56K.
  • Charles River Laboratories made up 0.04% of Primecap Management's portfolio in Q2 2026, its #191 holding.
  • Primecap Management first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
  • Primecap Management's Charles River Laboratories position peaked at $151M in Q3 2021.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Primecap Management's 13F filing for Q2 2026, filed 14 Aug 2026.